Oak Longevity Review
Affordable compounded GLP-1 with no hidden membership fees, plus longevity peptides.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Quick Verdict
Affordable compounded GLP-1 with no hidden membership fees, plus longevity peptides.
Who it's for: Oak Longevity makes the most sense for value-driven buyers who want both a compounded GLP-1 and a small longevity stack — peptides, NAD+, or sermorelin — without paying premium-clinic pricing. The flat per-medication model with no membership fee is genuinely cost-effective. As a newer brand, the public review history is thinner than established competitors, which is the main reason to consider alternatives if trust signals matter to you.
Bottom line: A reasonable lower-cost combined GLP-1 + longevity option. The flat per-medication pricing with no membership fee and free shipping is genuinely competitive. The main limitation is brand maturity — Oak Longevity has fewer public reviews than Eden or Telos Rx. If established brand recognition matters, look at Eden; if you want the lowest all-in cost for GLP-1 + peptides, Oak is worth a closer look.
- No hidden membership fees or dose surcharges
- Free shipping included
- Combined GLP-1 + longevity positioning in one clinic
- Flat per-medication pricing — pay only for what you use
- Newer brand with less public review history
- Smaller catalog than category leaders
Pros & Cons In Detail
Oak Longevity Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Oak Longevity.
| Program / Membership Fee | No membership fee |
| Medication Cost (From) | From $130 – $399/mo |
Flat per-medication pricing with no membership fee, free shipping, and no dose surcharges. Compounded semaglutide, tirzepatide, and longevity peptides are each priced individually, so you only pay for what you use. No long-term contracts required.
Who Oak Longevity Is For
Oak Longevity makes the most sense for value-driven buyers who want both a compounded GLP-1 and a small longevity stack — peptides, NAD+, or sermorelin — without paying premium-clinic pricing. The flat per-medication model with no membership fee is genuinely cost-effective. As a newer brand, the public review history is thinner than established competitors, which is the main reason to consider alternatives if trust signals matter to you.
Buyers seeking compounded GLP-1 plus a small longevity stack at a transparent flat price.
Signature Programs
- ›Compounded GLP-1
- ›NAD+ and glutathione
- ›Sermorelin and tadalafil
Medication Formulary
The Bottom Line
A reasonable lower-cost combined GLP-1 + longevity option. The flat per-medication pricing with no membership fee and free shipping is genuinely competitive. The main limitation is brand maturity — Oak Longevity has fewer public reviews than Eden or Telos Rx. If established brand recognition matters, look at Eden; if you want the lowest all-in cost for GLP-1 + peptides, Oak is worth a closer look.
With an editor score of 4.1 / 5 across cost, experience, and trust, Oak Longevity is one of the specialty options in the glp-1 weight loss category we cover.
See how Oak Longevity compares in our full glp-1 weight loss rankings, or read the Best NAD+ Injection Providers Online (2026) guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss vs 2.4% placebo at 68 weeks in the STEP 1 trial.
- FDA Federal Register 2024 (Semaglutide shortage end) · FDA removed semaglutide from the drug shortage list in October 2024, ending the legal basis for compounding.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1) · Tirzepatide 15 mg produced 20.9% mean weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1.
- FDA Federal Register 2024 (Tirzepatide shortage end) · FDA removed tirzepatide from the drug shortage list in October 2024.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
